Janux Therapeutics develops immunotherapy drugs that direct the immune system's T cells to attack tumors and autoimmune disease. It last closed at $10.08 on Nov 20, down 2.04% on the day. The next earnings report for JANX is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, JANX reported EPS of -$0.34 on revenue of $9.3M, with revenue down 7.1% from a year ago. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months JANX insiders bought $0 of stock on the open market and sold $457K, according to SEC Form 4 filings.
AI Auto Pilots
Is JANX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold JANX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on JANXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
JANX · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 42% below its 20 day and 58% below its 50 day average. It is 52% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $10.05, and the nearest resistance the Pivot at $10.22.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.7%/day
Key levels
$35.3452 week high+250.6%
$16.41100 day average+62.8%
$15.9650 day average+58.3%
$15.28200 day average+51.6%
$14.3420 day average+42.3%
$14.03Swing high (Jun 10)+39.2%
$10.40Pivot R1+3.2%
$10.22Pivot+1.4%
$10.08Last close
$10.0552 week low−0.3%
$9.91Pivot S1−1.7%
Indicators
RSI (14)
25.32
Oversold below 30
Oversold
MACD
-1.88
Below its signal line
Bearish
Stochastic
1.1
Near the bottom of its range
Oversold
ADX (14)
35.7
Trending down
Williams %R
-99.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−42.8%
Change over 10 sessions
Bearish
ATR (14)
$0.97
Typical daily range, 9.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 21.3%/day
Key levels
$35.3452 week high+250.6%
$16.41100 day average+62.8%
$15.9650 day average+58.3%
$15.28200 day average+51.6%
$14.3420 day average+42.3%
$14.03Swing high (Jun 10)+39.2%
$10.40Pivot R1+3.2%
$10.22Pivot+1.4%
$10.08Last close
$10.0552 week low−0.3%
$9.91Pivot S1−1.7%
Indicators
RSI (14)
32.55
Weak, oversold below 30
Neutral
MACD
-0.59
Below its signal line
Bearish
Stochastic
17.8
Near the bottom of its range
Oversold
ADX (14)
20.3
Weak trend
Williams %R
-99.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-319.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−41.0%
Change over 10 sessions
Bearish
ATR (14)
$2.14
Typical daily range, 21.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for JANX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how JANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow JANX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for JANXHow many large options trades hit JANX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in JANX in the last 90 days.
From SEC Form 4 filings by JANX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JANX is in one of them and how their past JANX trades turned out.
Janux Therapeutics is a biopharmaceutical company based in San Diego, California. It develops immunotherapy drugs that direct the body's T cells to attack tumors, and it is also developing treatments for autoimmune diseases. Its lead candidates are in clinical trials for prostate cancer and other solid tumors. The company's drug candidates are aimed at cancer patients and people living with autoimmune conditions.